The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Packaged breads and refined grain products may increase the odds of developing IBD, while minimally processed fresh bread and ...

Novartis is hoping to gain approval for its Sjögren’s disease drug after it met the endpoints in two Phase III trials. The ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Roche (RHHBY) and Novartis (NVS) are scheduled to meet with Swiss officials this week amid U.S. tariff threats on pharma ...

Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

A 47-year-old pharmaceutical executive from New Jersey has been charged with aggravated manslaughter, vehicular homicide and assault by auto in connection with a high-speed, wrong-way crash that ...